The benefits could be more important than the risks for most who use it
Warning signs include: Sudden rash or hives spreading across the body Generalized itching that is not isolated to the application site Swelling of the face, lips, tongue, or throat Difficulty breathing or shortness of breath Symptoms suggestive of a severe allergic reaction (anaphylaxis) require prompt medical attention
You may also want to review past blogs that describe both neuroprotective and symptomatic strategies that are in clinical trial: Future Parkinsons disease treatments in clinical trial Therapies for non-motor symptoms in clinical trials Repurposed medications being studied for PD Medications in clinical trials 2023 Parkinsons disease medication pipeline Alpha-synuclein strategies for Parkinsons disease Five potential medications in the PD research pipeline 1
Falling asleep faster & stay asleep longer
(eClinicalMedicine, 2024), a randomized, double-blinded, two-centre, phase 2 trial of once-weekly semaglutide 1.0 mg versus placebo in 64 adults with increased fracture risk